EGFR and neoplasm: Combination of a systemic STING agonist, MSA-2 (Figure 6), with osimertinib, a third-generation EGFR inhibitor, leads to a decline in advanced pulmonary embolism, perhaps through the action of STING on the tumor microenvironment, in mice [245].